Cargando…

ABO gene editing for the conversion of blood type A to universal type O in Rh(null) donor‐derived human‐induced pluripotent stem cells

The limited availability of red cells with extremely rare blood group phenotypes is one of the global challenges in transfusion medicine that has prompted the search for alternative self‐renewable pluripotent cell sources for the in vitro generation of red cells with rare blood group types. One such...

Descripción completa

Detalles Bibliográficos
Autores principales: Petazzi, Paolo, Miquel‐Serra, Laia, Huertas, Sergio, González, Cecilia, Boto, Neus, Muñiz‐Diaz, Eduardo, Menéndez, Pablo, Sevilla, Ana, Nogués, Núria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593258/
https://www.ncbi.nlm.nih.gov/pubmed/36281739
http://dx.doi.org/10.1002/ctm2.1063
_version_ 1784815121216831488
author Petazzi, Paolo
Miquel‐Serra, Laia
Huertas, Sergio
González, Cecilia
Boto, Neus
Muñiz‐Diaz, Eduardo
Menéndez, Pablo
Sevilla, Ana
Nogués, Núria
author_facet Petazzi, Paolo
Miquel‐Serra, Laia
Huertas, Sergio
González, Cecilia
Boto, Neus
Muñiz‐Diaz, Eduardo
Menéndez, Pablo
Sevilla, Ana
Nogués, Núria
author_sort Petazzi, Paolo
collection PubMed
description The limited availability of red cells with extremely rare blood group phenotypes is one of the global challenges in transfusion medicine that has prompted the search for alternative self‐renewable pluripotent cell sources for the in vitro generation of red cells with rare blood group types. One such phenotype is the Rh(null), which lacks all the Rh antigens on the red cell membrane and represents one of the rarest blood types in the world with only a few active blood donors available worldwide. Rh(null) red cells are critical for the transfusion of immunized patients carrying the same phenotype, besides its utility in the diagnosis of Rh alloimmunization when a high‐prevalence Rh specificity is suspected in a patient or a pregnant woman. In both scenarios, the potential use of human‐induced pluripotent stem cell (hiPSC)‐derived Rh(null) red cells is also dependent on ABO compatibility. Here, we present a CRISPR/Cas9‐mediated ABO gene edition strategy for the conversion of blood type A to universal type O, which we have applied to an Rh(null) donor‐derived hiPSC line, originally carrying blood group A. This work provides a paradigmatic example of an approach potentially applicable to other hiPSC lines derived from rare blood donors not carrying blood type O.
format Online
Article
Text
id pubmed-9593258
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95932582022-10-26 ABO gene editing for the conversion of blood type A to universal type O in Rh(null) donor‐derived human‐induced pluripotent stem cells Petazzi, Paolo Miquel‐Serra, Laia Huertas, Sergio González, Cecilia Boto, Neus Muñiz‐Diaz, Eduardo Menéndez, Pablo Sevilla, Ana Nogués, Núria Clin Transl Med Research Articles The limited availability of red cells with extremely rare blood group phenotypes is one of the global challenges in transfusion medicine that has prompted the search for alternative self‐renewable pluripotent cell sources for the in vitro generation of red cells with rare blood group types. One such phenotype is the Rh(null), which lacks all the Rh antigens on the red cell membrane and represents one of the rarest blood types in the world with only a few active blood donors available worldwide. Rh(null) red cells are critical for the transfusion of immunized patients carrying the same phenotype, besides its utility in the diagnosis of Rh alloimmunization when a high‐prevalence Rh specificity is suspected in a patient or a pregnant woman. In both scenarios, the potential use of human‐induced pluripotent stem cell (hiPSC)‐derived Rh(null) red cells is also dependent on ABO compatibility. Here, we present a CRISPR/Cas9‐mediated ABO gene edition strategy for the conversion of blood type A to universal type O, which we have applied to an Rh(null) donor‐derived hiPSC line, originally carrying blood group A. This work provides a paradigmatic example of an approach potentially applicable to other hiPSC lines derived from rare blood donors not carrying blood type O. John Wiley and Sons Inc. 2022-10-25 /pmc/articles/PMC9593258/ /pubmed/36281739 http://dx.doi.org/10.1002/ctm2.1063 Text en © 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Petazzi, Paolo
Miquel‐Serra, Laia
Huertas, Sergio
González, Cecilia
Boto, Neus
Muñiz‐Diaz, Eduardo
Menéndez, Pablo
Sevilla, Ana
Nogués, Núria
ABO gene editing for the conversion of blood type A to universal type O in Rh(null) donor‐derived human‐induced pluripotent stem cells
title ABO gene editing for the conversion of blood type A to universal type O in Rh(null) donor‐derived human‐induced pluripotent stem cells
title_full ABO gene editing for the conversion of blood type A to universal type O in Rh(null) donor‐derived human‐induced pluripotent stem cells
title_fullStr ABO gene editing for the conversion of blood type A to universal type O in Rh(null) donor‐derived human‐induced pluripotent stem cells
title_full_unstemmed ABO gene editing for the conversion of blood type A to universal type O in Rh(null) donor‐derived human‐induced pluripotent stem cells
title_short ABO gene editing for the conversion of blood type A to universal type O in Rh(null) donor‐derived human‐induced pluripotent stem cells
title_sort abo gene editing for the conversion of blood type a to universal type o in rh(null) donor‐derived human‐induced pluripotent stem cells
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593258/
https://www.ncbi.nlm.nih.gov/pubmed/36281739
http://dx.doi.org/10.1002/ctm2.1063
work_keys_str_mv AT petazzipaolo abogeneeditingfortheconversionofbloodtypeatouniversaltypeoinrhnulldonorderivedhumaninducedpluripotentstemcells
AT miquelserralaia abogeneeditingfortheconversionofbloodtypeatouniversaltypeoinrhnulldonorderivedhumaninducedpluripotentstemcells
AT huertassergio abogeneeditingfortheconversionofbloodtypeatouniversaltypeoinrhnulldonorderivedhumaninducedpluripotentstemcells
AT gonzalezcecilia abogeneeditingfortheconversionofbloodtypeatouniversaltypeoinrhnulldonorderivedhumaninducedpluripotentstemcells
AT botoneus abogeneeditingfortheconversionofbloodtypeatouniversaltypeoinrhnulldonorderivedhumaninducedpluripotentstemcells
AT munizdiazeduardo abogeneeditingfortheconversionofbloodtypeatouniversaltypeoinrhnulldonorderivedhumaninducedpluripotentstemcells
AT menendezpablo abogeneeditingfortheconversionofbloodtypeatouniversaltypeoinrhnulldonorderivedhumaninducedpluripotentstemcells
AT sevillaana abogeneeditingfortheconversionofbloodtypeatouniversaltypeoinrhnulldonorderivedhumaninducedpluripotentstemcells
AT noguesnuria abogeneeditingfortheconversionofbloodtypeatouniversaltypeoinrhnulldonorderivedhumaninducedpluripotentstemcells